含有Epstein—Barr病毒膜抗原的重组表达质粒及其基因免疫

将Ｅｐｓｔｅｉｎ－Ｂａｒｒ（ＥＢ）病毒主要的膜抗原（ＭＡ）ＢＬＬＦ１基因片段插入ｐＨＤ１０１－３质粒的ＣＭＶ启动子下游,构建了真核表达质粒ｐＨＤ－ｇｐ３５０,并转染２９３细胞进行瞬间表达。用免疫荧光法从细胞膜检测到表达的抗原能与其单克隆抗体发生特异性结合。Ｗｅｓｔｅｍ－ｂｌｏｔ法证实,表达的抗原分子量为３５０ｋＤ。用能在真核细胞表达的重组质粒ｐＨＤ－ｇｐ３５０的ＤＮＡ,经Ｓｅｐｈａｒｏｓｅ ２Ｂ柱     

Epstein—Barr病毒膜抗原基因免疫的研究

将Ｅｐｓｔｅｉｎ－Ｂａｒｒ病毒（ＥＢＶ）膜抗原（ＭＡ）ＢＬＬＦ１基因,插入含有ＣＭＶ启动子的真核表达载体ｐｃＤＮＡ３下游ＢａｍＨＩ位点,构建成真核表达质粒ｐｃＤＮＡ３－ＭＡ。将纯化的ＤＮＡ注射Ｂａｌｂ／ｃ小鼠股四头肌。经免疫的动物产生抗ＥＢ病毒ＭＡ特异性的抗体和中和抗体,依赖抗体细胞介导的细胞毒作用（ＡＤＣＣ）,特异性Ｔ淋巴细胞增生性反应及细胞毒性Ｔ淋巴细胞（ＣＴＬ）杀伤作用。基因免疫与基因－蛋白     

Epstein-Barr病毒膜抗原基因免疫的研究

将Ｅｐｓｔｅｉｎ－Ｂａｒ病毒（ＥＢＶ）膜抗原（ＭＡ）ＢＬＬＦ１基因,插入含有ＣＭＶ启动子的真核表达载体ｐｃＤＮＡ３下游ＢａｍＨＩ位点,构建成真核表达质粒ｐｃＤＮＡ３－ＭＡ。将纯化的ＤＮＡ注射Ｂａｌｂ／ｃ小鼠股四头肌。经免疫的动物产生抗ＥＢ病毒ＭＡ特异性的抗体和中和抗体,依赖抗体细胞介导的细胞毒作用（ＡＤＣＣ）,特异性Ｔ淋巴细胞增生性反应及细胞毒性Ｔ淋巴细胞（ＣＴＬ）杀伤作用。基因免疫与基因－蛋白联合免疫效果相似。不同启动子控制下的ＭＡ基因,诱发小鼠免疫应答无明显差异。     

Epstein─Barr病毒膜抗原在中国仓鼠卵巢（CHO）细胞中的表达

将切去３’端穿膜序列的ＥＢ病毒膜抗原（ＭＡ）基因,插入ｐＳＶ２－ｄｈｆｒ质粒的ＳＶ４０早期启动子下游,构建了真核表达载体ｐＳＶ２－ｄｈｆｒＧＰＴＲ,使两个ＳＶ４０早期启动子分别调控ＭＡ和二氢叶酸还原酶（ｄｈｆｒ）基因。将该重组质粒转化ＣＨＯ－ｄｈｆｒ细胞,在选择培养基中筛选阳性克隆,用氨甲喋呤加压扩增,建立了表达ＥＢＶ－ＭＡ的克隆细胞系。ｗｅｓｔｅｒｎｂｌｏｔ分析证明,所表达的蛋白的分子量大约为３４０ｋｄ和２２０ｋｄ。经过细Ｓｅｐｈａｒｏｓｅ２Ｂ琼脂糖凝胶层析初步纯化的抗原与福氏佐剂混合免疫小鼠,２周后小鼠血清中出现明显的ｇｐ３４０／２２０特异性抗体,表明切去嵌膜区结构的ＥＢＶ－ＭＡ基因在ＣＨＯ细胞中的表达产物具有同天然膜抗原相似的分子量大小、糖基化程度、免疫特异性和免疫原性,可望成为ＥＢ病毒人用基因工程亚单位疫苗。     

在昆虫细胞中表达EB病毒壳抗原及其在诊断中的应用

本研究的目的是以昆虫杆病毒为感染为载体表达ＥＢ病毒壳蛋白的主要多肽ｇｐ１２５,用间接免疫荧光和免疫的印迹技术证明表达产物的特异性,表达产物位于感染细胞的胞闪内,分子量约１００ｋＤ,用免疫Ｄｏｔ法检查感染细胞裂解物中存在特异性表达产物的量,重组病毒裂解产物免疫小鼠后,能产生与ＶＣＡ反应的抗体,重组病毒感染的细胞为靶细胞,与Ｂ９５－８细胞片平行检查人血清中ＶＣ／ＩｇＧ和ＶＣＡ／ＩｇＡ抗体,确定表达产物     

表达流行性感冒病毒血凝素蛋白的重组腺病毒的构建

用ＲＴ－ＰＣＲ方法扩增流感病毒血凝素基因,将其克隆到５型腺病毒载体质粒ｐＡＤ５Ｃ中。用此质粒与ＥｃｏＲＩ酶切回收的５型腺病毒基因组片段共转染２９３细胞,通过ＰＣＲ初步筛选得到重组病毒。ＳＤＳ－ＰＡＧＥ电泳、Ｗｅｓｔ－ｅｒｎ ｂｌｏｔ重组病毒能表达流感病毒的血凝素蛋白。此重组病毒经滴鼻免疫Ｂａｌｂ／Ｃ小鼠,ＥＬＩＳＡ实验证明能诱导小鼠产生针对流感的循环抗体ＩｇＧ和分泌型抗体ＩｇＡ。本实验证明,利用Ｅ     

用核酸免疫技术制备抗丙肝病毒C区单克隆抗体

用丙肝病毒Ｃ＋Ｅ１区真核表达质粒ｐｃＤＮＡ－ＨＣＶ／Ｃ＋Ｅ１按４００ｕｇ／只剂量免疫ＢＡＬＢ／Ｃ小鼠,１４周后同一剂量再加强免疫一次。加强免疫后２周,在５０％ＰＥＧ１４５０介导下将脾细胞与ＳＰ２／０小鼠骨髓瘤细胞（５１）融合。实验结果融合率达５４．３％（３１３／５７６）。阳性率为５．４％（１７”３１３）。克隆化后得到６株稳定分泌抗丙肝病毒Ｃ区单克隆抗体杂交瘤细胞株。这６株杂交瘤均产生ＩｇＭ抗体,接种ＢＡＬＢ／Ｃ小鼠后产生腹水的效价为１６４－１３２０（ＥＬＩＳＡ）。     

抗丙肝病毒核心抗原单克隆抗体的研制与初步鉴定

用基因工程重组技术获得的丙肝病毒（ＨＣＶ）核心蛋白抗原与鼠血清白蛋白交联后免疫Ｂａｌｂ／ｃ小鼠,用杂交瘤技术成功地建立了４株稳定分泌抗核心抗原单克隆抗体的杂交瘤细胞,试验结果表明,该４株ＭｃＡｂｓ与免疫抗原及核心区Ｃ３３肽、ＣＰ９、ＣＰ１０抗原有较强的抗原－抗体反应,与ＨＣＶ ＮＳ３、ＮＳ４、ＮＳ５无反应,在竞争ＥＬＩＳＡ中,对ＨＣＶ－ＩｇＧ阳性血清有较好的抑制作用。４株ＭｃＡｂｓ中３株为ＩｇＧ２     

CD23分子结构和功能的研究进展

ＣＤ２３是一个分子量４５ｋＤ单链糖蛋白,主要表达在ｓＩｇＤ和ｓＩｇＭ双阳性Ｂ细胞目前已知ＣＤ２３有两个配体：即ＩｇＥ和ＣＤ２１。完整的ＣＤ２３分子及其可溶性片段具有介导Ｂ细胞生长,诱导Ｂ细胞转化,维持ＥＢＶＤＮＡ＾＋Ｂｕｒｋｉｔｔ淋巴瘤细胞系和ＥＢＶ转化的Ｂ细胞系的自生长以及诱导ＩｇＥ的合成等多种生物学功能,本着重介绍ＣＤ２３分子的ＢＣＧＦ作用。     

丙型肝炎病毒C33_c单克隆抗体的研制和鉴定

用丙型肝炎病毒重组蛋白Ｃ３３_ｃ抗原免疫ＢＡＬＢ／ｃ小鼠,运用杂交瘤技术成功地建立了７株能稳定分泌抗Ｃ３３_ｃ单克隆抗体的杂交瘤细胞１Ｈ６Ｄ２、２Ｇ１Ａ６、３Ａ４Ａ８、３Ｅ３Ｅ７、４Ｇ１２Ｃ１０、４Ａ１０Ｃ２、５Ｆ４Ｂ６．试验结果表明,７株ＭｃＡｂｓ具有良好的ＨＣＶ特异性,间接ＥＬＩＳＡ法测得小鼠腹水ＭｃＡｂ效价为１：１０￣４－１：４×１０￣４;竞争抑制实验和相加指数测定证实７株ＭｃＡｂｓ识别相关的抗原表位;７株ＭｃＡｂｓ中１株为ＩｇＭ（５Ｆ４Ｂ６）,其它６株为ＩｇＧ（２ａ）。     

DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen

Epstein-Barr virus (EBV) is a human pathogen that is involved in numerous diseases and tumors. Since the EBV infection occurs in the early ages of life, and most of the population is subsequently exposed to EBV, the conventional method of vaccination to induce the prophylactic immunity cannot be considered effective in coping with the virus infection. In this study, we tested whether the injection of a plasmid vector that contained the gene for glycoprotein 350 (gp350), which had been identified as a ligand for virus' adsorption and a target for virus neutralizing antibodies, could induce effective immune responses against the antigen. As a result, the injection of the constructed plasmid vector into mice induced the production of gp350-specific antibodies. A major isotype of the gp350-specific antibodies was IgG1. The antibodies efficiently mediated the antibody-dependent cellular cytotoxicity against the cells expressing the gp350 antigen. In addition, the injection of the constructed plasmid vector stimulated the precursor T cell population that was specific to the gp350 antigen. In addition, gp350-specific cytotoxic T lymphocytes were efficiently stimulated by the injection of the constructed plasmid vector. These results suggested that the injection of the plasmid vector, containing the gp350 gene of Epstein-Barr virus, could be one of the most effective ways to induce both prophylactic and therapeutic vaccinations against the virus infection.     

Epstein-Barr病毒基因工程活疫苗人体免疫的初步研究

Epstein-Barr(EB)病毒的原发感染发生在儿童时期,在我国3～5岁儿童的感染率为70％～90％。感染后终生带毒,并经唾液不断排出病毒。我国南方是鼻咽癌高发区,其发病率和死亡率均占恶性肿瘤的第一位。早期诊断方法的改进和早期治疗,使鼻咽癌治疗后的5年生存率明显增加,但不能降低发病率。EB病毒疫苗有可能成为控制该病的有效手段之一。 Epstein等人从淋巴母细胞株(B95-8细胞)细胞表面提取EB病毒膜抗原(MA),用于免疫棉顶猴能产生中和抗体。免疫动物能抵抗EB病毒攻击后所诱发的恶性淋巴瘤。该中和抗体在体外能中和EB病毒的转化活性。EB病毒的主要膜抗原(MA)是由分子量220kD和     

表达EB病毒主要膜蛋白的非复制型重组痘苗病毒毒力及体液免疫反应

利用表达EBV GP350/220的非复制型重组痘苗病毒VMA△CK及复制性重组痘苗病毒VMA,注射乳鼠脑内,观察毒力。同时,用VMA△CK及VMA免疫Bal/c小鼠,经ELISA测定其特异性抗体水平。免疫血清用抗体中和EBV感染Raji细胞抑制产生早期抗原（NEA）法测定其中和抗体滴度。将免疫血清与P3HR-1细胞共同孵育后,测上清中EBV滴度以观察抗体体制EBV从P3HR-1细胞中释放效应。结果发现,VMA△CK毒力明显低于VMA,其LD50为4.5PFU/0.02ml,而VMA△CK的LD50大于10^6PFU/0.02ml。VMA△CK与VAM免疫血清中抗GP350/220抗体水平无明显差异,而初兔后抗痘苗病毒抗体水平VMA免疫组较VMA△CK免疫组高5倍左右。VMA△CK免疫组血清中和抗体水平没有明显差异。VMA△CK免疫血清稀释度与P3HR-1细胞培养上清中EBV滴度有剂量依赖关系。     

Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Antibody-mediated inhibition of Epstein-Barr virus (EBV) release from the EBV-productive cell lines P3HR-1 and B95-8 was probed with two monoclonal antibodies (MAbs), 72A1 and 2L10, which immunoprecipitated the same EBV membrane antigen (MA) gp350/220 found with the 1B6 MAb with which inhibition of EBV release from P3HR-1 cells was first described. These three MAbs were not equivalent in either MA reactivities or functional effects, reflecting the variable expression of different epitopes of gp350/220. 1B6 recognized MA on P3HR-1 cells, which expressed predominately the gp220 form of MA. 1B6 did not recognize (or barely recognized) a determinant on B95-8 cells. MAbs 2L10 and 72A1 reacted as well with B95-8 cells as they did with P3HR-1 cells. MAbs 1B6 and 2L10 neutralized neither P3HR-1 nor B95-8 virus, but 72A1 neutralized both viruses. MAbs 1B6 and 72A1 inhibited P3HR-1 virus release, as measured by the assay for infectious virus and by DNA hybridization analysis of released virus, but 2L10 had no such activity. 72A1 (but not 1B6) inhibited release of EBV from B95-8 cells. These experiments pointed to the presence of three different epitopes on gp350/220, identified with the respective MAbs and having varying involvement in virus neutralization and virus release inhibition.     

Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies

The requirement of high doses of interferon (IFN) during therapy severely restrict its application. Thus a model using an Epstein-Barr virus (EBV) membrane antigen (MA) specific monoclonal antibody (MAb) was developed to assess the feasibility of coupling minimal amounts of IFN to a MAb and specifically delivering the IFN to the target cells. Coupled IFN was first shown to retain fully both its anti-viral and anti-proliferative properties when tested on human tumor cell lines QIMR-WIL (EBV-MA+) and the U-266 (EBV-MA-). A series of in vitro pulsing experiments demonstrated the specific targeting of both the anti-viral and anti-proliferative properties of IFN to the EBV-MA+ QIMR-WIL cells and not EBV-MA- cell lines.     

Polyethylenimine-mediated suicide gene transfer induces a therapeutic effect for hepatocellular carcinoma in vivo by using an Epstein-Barr virus-based plasmid vector

The present study aimed to establish a novel efficient nonviral strategy for suicide gene transfer in hepatocellular carcinoma (HCC) in vivo. We employed branched polyethylenimine (PEI) and combined it with Epstein-Barr virus (EBV)-based plasmid vectors. The HCC cells transfected with an EBV-based plasmid carrying the herpes simplex virus-1 thymidine kinase (HSV-1 Tk) gene (pSES.Tk) showed up to 30-fold higher susceptibilities to ganciclovir (GCV) than those transfected with a conventional plasmid vector carrying the HSV-1 Tk gene (pS.Tk). The therapeutic effect in vivo was tested by intratumoral injection of the plasmids into HuH-7 hepatomas transplanted into C.B-17 scid/scid mutant (SCID) mice and subsequent GCV administrations. Treatment with pSES.Tk, but not pS.Tk, markedly suppressed growth of hepatomas in vivo, resulting in a significantly prolonged survival period of the mice. These findings suggest that PEI-mediated gene transfer system can confer efficient expression of the suicide gene in HCC cells in vivo by using EBV-based plasmid vectors.     

Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo

To date, no gene transfer vector has produced prolonged gene expression following a single intravenous injection and then efficiently re-expressed the delivered gene following repeated systemic injection into immunocompetent hosts. To overcome these limitations, a gene therapy regimen using non-replicating Epstein-Barr virus (EBV)-based expression plasmids was developed. One plasmid contains the FR (EBV family of repeats) sequence and the expressed gene. The other encodes Epstein-Barr nuclear antigen 1 (EBNA-1), but lacks FR. Although unable to replicate in mice, intravenous co-injection of EBV-based plasmids in cationic liposome-DNA complexes (CLDCs) substantially prolonged luciferase gene expression. The use of a two-vector system limited host exposure to the EBNA-1 gene product. Furthermore, this EBV-based vector system could be intravenously re-injected multiple times into immunocompetent mice without loss of transfection efficiency. Use of this vector system significantly improved the therapeutic efficacy of the biologically important human granulocyte colony-stimulating factor gene. Delivery of the human granulocyte colony-stimulating factor gene in EBV-based plasmids increased circulating white blood counts for at least 2 months following a single CLDC-based intravenous co-injection. Conversely, white blood counts were never elevated following injection of CLDCs lacking EBV-derived elements. Thus, this EBV-based plasmid vector system both markedly prolongs gene expression at therapeutic levels and efficiently and repeatedly re-transfects immunocompetent hosts. These properties of EBV-based plasmid vectors appear to be due, at least in part, to the documented abilities of the EBNA-1 protein both to retain FR-containing DNA intracellularly and within the nucleus and to block anti-EBNA-1 cytotoxic T cell responses.     

Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells

Epstein-Barr virus (EBV) invasion of B-lymphocytes involves EBV gp350/220 binding to B-lymphocyte CR2. The anti-gp350 monoclonal antibody (mAb)-72A1 Fab inhibits this binding and therefore blocks EBV invasion of target cells. However, gp350/220 regions interacting with mAb 72A1 and involved in EBV invasion of target cells have not yet been identified. This work reports three gp350/220 regions, defined by peptide 11382, 11389, and 11416 sequences, that are involved in EBV binding to B-lymphocytes. Peptides 11382, 11389, and 11416 bound to CR2(+) but not to CR2(-) cells, inhibited EBV invasion of cord blood lymphocytes (CBLs), were recognized by mAb 72A1, and inhibited mAb 72A1 binding to EBV. Peptides 11382 and 11416 binding to peripheral blood lymphocytes (PBLs) induced interleukin-6 protein synthesis in these cells, this phenomenon being inhibited by mAb 72A1. The same behavior has been reported for gp350/220 binding to PBLs. Anti-peptide 11382, 11389, and 11416 antibodies inhibited EBV binding and EBV invasion of PBLs and CBLs. Peptide 11382, 11389, and 11416 sequences presented homology with the C3dg regions coming into contact with CR2 (C3dg and gp350 bound to similar CR2 regions). These peptides could be used in designing strategies against EBV infection.     

Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays

The Epstein-Barr virus (EBV) envelope glycoprotein 350/220 (gp350/220) is the most abundant molecule on the viral surface and it is responsible for the initial viral attachment to cell surface of the host. As many other viral envelope proteins, it is highly glycosylated, not least with O-linked glycans, most of which essential for EBV life cycle. EBV gp350/220 is also a primary target for neutralizing antibodies in the human hosts and a promising candidate for an EBV vaccine. Here we showed that recombinant GalNAc transferases can glycosylate scan peptides of the EBV gp350/220 envelope protein immobilized on microarray glass slides. We also identified serum IgG antibodies to a selection of peptides and O-glycopeptides, whereas sera from EBV-IgG negative individuals remained negative. We here describe novel glycopeptide epitopes present within immunodominant stretches of EBV gp350/220 and demonstrate a remarkable variability between individual samples with respect to their reactivity patterns to peptides and glycopeptides. The study provides additional insights into the complex B-cell response towards the EBV gp350/220 envelope protein, which may have implications for diagnostic and vaccine developments.